| 主权项 |
1. A method of treating chronic immune hyperactivity in an individual, the method comprising administering to an individual having chronic immune hyperactivity an effective amount of a SIRT1 activator, wherein the SIRT1 activator is a compound of the formula:or a salt thereof, wherein
R19 is selected from:wherein:
each Z10, Z11, Z12 and Z13 is independently selected from N, CR20 or CR1′; and each Z14, Z15 and Z16 is independently selected from N, NR1′, S, O, CR20, or CR1′, wherein: zero to two of Z10, Z11, Z12 or Z13 are N; at least one of Z14, Z15 and Z16 is N, NR1′, S or O; zero to one of Z14, Z15 and Z16 is S or O; zero to two of Z14, Z15 and Z16 is N or NR1′; zero to one R30 is a solubilizing group; and zero to one R1′ is an optionally substituted C1-C3 straight or branched alkyl; each R20 is independently selected from H or a solubilizing group; R21 is selected from —NR1′—C(O)—, —NR1′—S(O)2—, —NR1′—C(O)—NR1′—, —NR1′—C(S)—NR1′—NR1′—C(S)— NR1′—CR1′R1′—, —NR1′—C(O)—CR1′R1′—NR1′—, —NR1′—C(═NR1′)—NR1′—, —C(O)—NR1′—C(O)—NR1′—, —CR1′R1′—, —NR1′—C(O)—C(O)—CR1′═CR1′—, —NR1′—S(O)2—NR1′–—NR1′—C(O)—NR1′—S(O)2—, —NR1′—CR1′R1′—C(O)—NR1′—, —CR1′R1′—C(O)—NR1′—, —NR1′—C(O)—CR1′═CR1′—CR1′R1′—, —NR1′—C(═N—CN)—NR1′—, —NR1′—C(O)—CR1′R1′—O—, —NR1′—C(O)—CR1′R1—CR1′R1′—O—, —NR1′—S(O)2—CR1′R1′—, —NR1′—S(O)2—CR1′R1′—CR1′R1′—, —NR1′— C(O)—CR1′R1′—; —NR1′—C(O)—CR1′R′1—CR1′R′1—, —NR1′—C(S)—NR1′—CR1′R′1—CR1′R′1—, —NR1′—C(O)—O—,wherein each R1′ is independently selected from H or optionally substituted C1-C3 straight or branched alkyl; and
R31 is selected from an optionally substituted monocyclic or bicyclic aryl, or an optionally substituted monocyclic or bicyclic heteroaryl,wherein the chronic immune hyperactivity results from an immunodeficiency virus infection.
|
